175 related articles for article (PubMed ID: 32973816)
1. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
Wen L; Zou X; Chen Y; Bai X; Liang T
Front Immunol; 2020; 11():2076. PubMed ID: 32973816
[TBL] [Abstract][Full Text] [Related]
2. Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC.
Matsuura N; Koh G; Konishi C; Minamino S; Takahara Y; Harada H; Kodama K; Emoto M
Cancer Immunol Immunother; 2018 Sep; 67(9):1417-1424. PubMed ID: 29995236
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review.
Gauci ML; Laly P; Vidal-Trecan T; Baroudjian B; Gottlieb J; Madjlessi-Ezra N; Da Meda L; Madelaine-Chambrin I; Bagot M; Basset-Seguin N; Pages C; Mourah S; Boudou P; Lebbé C; Gautier JF
Cancer Immunol Immunother; 2017 Nov; 66(11):1399-1410. PubMed ID: 28634815
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial.
Wang K; Xiang YJ; Yu HM; Cheng YQ; Liu ZH; Qin YY; Shi J; Guo WX; Lu CD; Zheng YX; Zhou FG; Yan ML; Zhou HK; Liang C; Zhang F; Wei WJ; Lau WY; Li JJ; Liu YF; Cheng SQ
Nat Med; 2024 Mar; 30(3):708-715. PubMed ID: 38242982
[TBL] [Abstract][Full Text] [Related]
5. Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report.
Martin-Liberal J; Furness AJ; Joshi K; Peggs KS; Quezada SA; Larkin J
Cancer Immunol Immunother; 2015 Jun; 64(6):765-7. PubMed ID: 25828465
[TBL] [Abstract][Full Text] [Related]
6. Clinical and immunological characteristics of PD-1 associated fulminant type 1 diabetes mellitus.
Qiu J; Luo S; Yin W; Li X; Zhou Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Jan; 48(1):49-58. PubMed ID: 36935177
[TBL] [Abstract][Full Text] [Related]
7. Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report.
Fetter T; Fietz S; Bertlich M; Braegelmann C; de Vos-Hillebrand L; Wenzel J; Heine A; Landsberg J; Jansen P
Front Immunol; 2024; 15():1342845. PubMed ID: 38571955
[TBL] [Abstract][Full Text] [Related]
8. Effects of PD-1 blockade on ovarian follicles in a prepubertal female mouse.
Xu PC; Luan Y; Yu SY; Xu J; Coulter DW; Kim SY
J Endocrinol; 2021 Nov; 252(1):15-30. PubMed ID: 34647523
[TBL] [Abstract][Full Text] [Related]
9. Challenges in autoimmune polyendocrine syndrome type 2 with the full triad induced by anti-programmed cell death 1: a case report and review of the literature.
Pan Q; Li P
Front Immunol; 2024; 15():1366335. PubMed ID: 38707904
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy.
Wu L; Carlino MS; Brown DA; Long GV; Clifton-Bligh R; Mellor R; Moore K; Sasson SC; Menzies AM; Tsang V; Gunton JE
J Clin Endocrinol Metab; 2024 Apr; 109(5):1301-1307. PubMed ID: 37997380
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor-associated colitis in unresectable hepatocellular carcinoma: two cases of early onset after treatment with durvalumab plus tremelimumab.
Abe H; Endo K; Kuroda H; Oikawa T; Abe T; Ito A; Suzuki A; Yoshida Y; Kakisaka K; Matsumoto T
Clin J Gastroenterol; 2024 Apr; 17(2):307-310. PubMed ID: 38185741
[TBL] [Abstract][Full Text] [Related]
12. Checking the Checkpoint Inhibitors: A Case of Autoimmune Diabetes After PD-1 Inhibition in a Patient with HIV.
Hughes MS; Pietropaolo M; Vasudevan MM; Marcelli M; Nguyen H
J Endocr Soc; 2020 Dec; 4(12):bvaa150. PubMed ID: 33225197
[TBL] [Abstract][Full Text] [Related]
13. Sintilimab-induced autoimmune diabetes mellitus manifesting as diabetic ketoacidosis in a patient with advanced esophageal squamous cell carcinoma.
Lai N; Fan X; Liu S
Acta Diabetol; 2024 May; 61(5):675-678. PubMed ID: 38334801
[No Abstract] [Full Text] [Related]
14. Simultaneous development of Graves' disease and type 1 diabetes during anti-programmed cell death-1 therapy: A case report.
Kurihara S; Oikawa Y; Nakajima R; Satomura A; Tanaka R; Kagamu H; Shimada A
J Diabetes Investig; 2020 Jul; 11(4):1006-1009. PubMed ID: 31926048
[TBL] [Abstract][Full Text] [Related]
15. Anti-PD-1 Therapy-A Potential Treatment for Myocardial Metastasis From Nasopharyngeal Carcinoma: A Case Report.
Tang X; Zhou W; Huang D; Chen L; Zhang G
Front Immunol; 2021; 12():688682. PubMed ID: 34804001
[TBL] [Abstract][Full Text] [Related]
16. Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review.
Zhao Z; Wang X; Bao XQ; Ning J; Shang M; Zhang D
Cancer Immunol Immunother; 2021 Jun; 70(6):1527-1540. PubMed ID: 33200250
[TBL] [Abstract][Full Text] [Related]
17. Sintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction: a case report and literature review.
Xiong W; Yang Z; Chen Y
Immunotherapy; 2024 Mar; ():. PubMed ID: 38530080
[TBL] [Abstract][Full Text] [Related]
18. Aggravation of diabetes, and incompletely deficient insulin secretion in a case with type 1 diabetes-resistant human leukocyte antigen DRB1*15:02 treated with nivolumab.
Matsumura K; Nagasawa K; Oshima Y; Kikuno S; Hayashi K; Nishimura A; Okubo M; Uruga H; Kishi K; Kobayashi T; Mori Y
J Diabetes Investig; 2018 Mar; 9(2):438-441. PubMed ID: 28418115
[TBL] [Abstract][Full Text] [Related]
19. Case report: A rare immune-related adverse effect: hepatic cavernous hemangioma induced by camrelizumab.
Zhang C; Wang G; Liu N; Li T; Zhu J; Hou H
Front Immunol; 2024; 15():1387465. PubMed ID: 38646529
[TBL] [Abstract][Full Text] [Related]
20. HLA-B27 association of autoimmune encephalitis induced by PD-L1 inhibitor.
Chang H; Shin YW; Keam B; Kim M; Im SA; Lee ST
Ann Clin Transl Neurol; 2020 Nov; 7(11):2243-2250. PubMed ID: 33031633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
